Efficacy and Tolerability of Two Commercial Hyperpigmentation Kits in the Treatment of Facial Hyperpigmentation and Photo-Aging

August 2012 | Volume 11 | Issue 8 | Original Article | 964 | Copyright © 2012

Abstract

Background: Hyperpigmentary disorders are common aesthetic skin conditions that can be very concerning to patients and both challenging and time-consuming for the physician to treat. Several companies commercialize hyperpigmentation kits for the lightening of dark spots and improvement of overall skin dyschromia. Unfortunately, clinical data from controlled studies to support the efficacy and tolerability of these kits are typically lacking
Objective: This investigator-blinded, randomized trial was undertaken to compare two commercial hyperpigmentation systems (kits) used for the treatment of facial hyperpigmentation and photo-aging.
Methods: Female subjects with at least mild facial hyperpigmentation and photo-aging were randomized to treatment with either the four product SkinMedica (SKM) regimen or the 7-product Obagi (OMP) regimen. Evaluations were conducted at baseline, 4, 8, and 12 weeks. Subjects were evaluated by the blinded investigator for clinical efficacy and tolerability using grading scales. Standardized digital photographs were taken at baseline and week 12. Self-assessment questionnaires were completed at week 12. Thirty-five females (SKM=17, OMP=18) completed the 12-week study.
Results: Both treatment regimens showed a significant improvement at week 12 (compared to baseline) for Overall Hyperpigmentation, Global Photo-aging and Sallowness. At week 12, there was no significant difference between treatment groups in Global Response to Treatment. Tolerability was good for both regimens based on investigator assessments. Subject self-assessments showed no consistent differences in efficacy between the two regimens. Similarly, there was no significant difference in subject satisfaction or intent to continue use between the two regimens.
Conclusion: This clinical study demonstrated that both systems were equally effective at reducing hyperpigmentation and global photo-aging in females with mottled pigmentation and photodamaged facial skin.

J Drugs Dermatol. 2012;11(8):964-968.

Purchase Original Article

Purchase a single fully formatted PDF of the original manuscript as it was published in the JDD.

Download the original manuscript as it was published in the JDD.

Contact a member of the JDD Sales Team to request a quote or purchase bulk reprints, e-prints or international translation requests.

To get access to JDD's full-text articles and archives, upgrade here.

Save an unformatted copy of this article for on-screen viewing.

Print the full-text of article as it appears on the JDD site.

→ proceed | ↑ close

INTRODUCTION

Disorders of hyperpigmentation including melasma, solar lentigines, ephelides, postinflammatory hyperpigmentation (PIH), mottled pigmentation, and dyschromia of photo-aging are conditions commonly seen in clinical dermatology practices. These pigmentary disorders can be both very distressing for patients and extremely challenging for the clinician to treat. While there are numerous treatment modalities available, topical hydroquinone (HQ) remains the gold standard for such pigmentary disorders. Hydroquinone has been used as a skin lightener for over 50 years and multiple clinical studies have documented its efficacy in various formulations.1-5 Hydroquinone is available in 2% formulations in many over-the-counter products and as a 4% prescription product and is rarely used alone in treating pigmentary disorders, but rather is typically combined with other agents in a regimen. Hydroquinone remains widely used for skin lightening despite concerns expressed regarding its safety from the FDA,6 presumably due to lack of any documented cases of either cutaneous or internal malignancy and extremely rare occurrences of exogenous ochronosis in the United States.7-9

Vitamin A derivatives (eg, retinol, tretinoin) have also been shown effective in the treatment of hyperpigmentation and are increasingly being employed in therapeutic regimens.10-14 These retinoids inhibit induced melanogenesis15,16 and enhance the depigmenting effects of HQ.17,18 In addition, topical retinoids modify the stratum corneum, facilitating the penetration of molecules such as HQ into the epidermis.19

This study was conducted to assess the efficacy and tolerability of two commercial hyperpigmentation systems (kits) used for the treatment of facial hyperpigmentation and photo-aging.

MATERIALS AND METHODS

The criteria for study participation included adult subjects aged 35 to 65 years, with Fitzpatrick skin types I-IV, with at least mild mottled hyperpigmentation of the face (corresponding to a score of 2 or more on a 5-point Hyperpigmentation Scale), and photodamaged facial skin (score of 2 or above on a 5-point Global Photo- aging Scale). Subjects must be willing to not use

↑ back to top


Related Articles